

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,261	09/26/2005	Sang Yup Lee	4240-123	6596
23448 7590 12/12/2007 INTELLECTUAL PROPERTY / TECHNOLOGY LAW PO BOX 14329			EXAMINER	
			JUNG, UNSU	
RESEARCH I	RIANGLE PARK, NC	27/09	ART UNIT PAPER NUMBER	
			1641	
			MAIL DATE	DELIVERY MODE
	•		12/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/541,261	LEE ET AL.			
		Examiner	Art Unit			
	-	Unsu Jung	1641			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)	1) Responsive to communication(s) filed on					
	This action is FINAL . 2b)⊠ This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
•	4)⊠ Claim(s) <u>1-10</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
,	Claim(s) is/are allowed.					
-	Claim(s) is/are rejected. Claim(s) is/are objected to					
	Claim(s) <u>1-10</u> are subject to restriction and/or	election requirement.				
Application Papers						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
10)□	Applicant may not request that any objection to the	drawing(s) be held in abeyance. S	ee 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority	under 35 U.S.C. § 119					
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)⊠ All b)□ Some * c)□ None of: 1.⊠ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s) Attachment(s) 4) Interview Summary (PTO-413)						
7) Natice of Profesorson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date.						
2) Notice of Dialisperson's Fatent Drawing Robert (1997) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application 6) Other:						

Art Unit: 1641

DETAILED ACTION

- 1. Preliminary amendments to claims 2, 4, 5, 7, and 8 filed on July 1, 2005 have been acknowledged and entered.
- 2. Claims 1-10 are pending.

Election/Restrictions

3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

List I: Linker Protein

A. Leptin

B. Malic enzyme

List II: Substrate Peptide Form

- A. Peptide monomer
 - i. Kemptide/SEQ ID NO:1
 - ii. Ab1/SEQ ID NO:8
- B. Dimmer of monomer-proline-monomer
 - i. Kemptide/SEQ ID NO:1
 - ii. Ab1/SEQ ID NO:8
- C. Multimer where monomers are linked to each other by a praline
 - i. Kemptide/SEQ ID NO:1
 - ii. Ab1/SEQ ID NO:8

List III: Reactive Protein

- A. Enzyme
 - i. Protein kinase A
 - ii. Ab1 kinase
- B. Antibody/fluorescence labeled antibody

Art Unit: 1641

i. Cy3-labeled anti-phosphorylation serine antibody

ii. Cy3-labeled anti-phosphorylation tyrosine antibody

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

List I: Linker Protein (claim 2)

- A. Leptin (claim 2)
- B. Malic enzyme (claim 2)

List II: Substrate Peptide Form (claims 3 and 4)

- A. Peptide monomer (claims 3 and 4)
 - i. Kemptide/SEQ ID NO:1 (claims 3 and 4)
 - ii. Ab1/SEQ ID NO:8 (claims 3 and 4)
- B. Dimmer of monomer-proline-monomer (claims 3 and 4)
 - i. Kemptide/SEQ ID NO:1 (claims 3 and 4)
 - ii. Ab1/SEQ ID NO:8 (claims 3 and 4)
- C. Multimer where monomers are linked to each other by a praline (claims 3 and 4)
 - i. Kemptide/SEQ ID NO:1 (claims 3 and 4)
 - ii. Ab1/SEQ ID NO:8 (claims 3 and 4)

List III: Reactive Protein (claims 7-10)

Page 4

Application/Control Number: 10/541,261

Art Unit: 1641

A. Enzyme (claims 7 and 8)

- i. Protein kinase A (claims 7 and 8)
- ii. Ab1 kinase (claims 7 and 8)
- B. Antibody/fluorescence labeled antibody (claims 7, 9, and 10)
 - i. Cy3-labeled anti-phosphorylation serine antibody (claims 7, 9, and 10)
 - ii. Cy3-labeled anti-phosphorylation tyrosine antibody (claims 7, 9, and 10)

The following claim(s) are generic: claims 1, 5, and 6.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each of the species of linker protein, substrate peptide, and reactive protein listed above lack the same special technical features.

4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions

Art Unit: 1641

unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Unsu Jung whose telephone number is 571-272-8506. The examiner can normally be reached on M-F: 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Unsu Jung/ Unsu Jung, Ph.D. Patent Examiner Art Unit 1641